June 16, 2026Journal of the American College of Cardiology
Revisiting Reperfusion Therapy in Inferior Myocardial Infarction
Key result
Thrombolysis for inferior MI mainly benefits high-risk patients, with no mortality data supporting primary angioplasty.
Why the study?
Although thrombolytic therapy is recommended regardless of infarct location, results are less impressive for inferior MI, and placebo-controlled randomized trials have not analyzed thrombolysis benefits across high-risk versus low-risk inferior MI subsets.
Does reperfusion therapy (thrombolysis or angioplasty) improve mortality in high-risk versus low-risk subsets of patients with inferior myocardial infarction?
Population
Patients with inferior myocardial infarction
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports thrombolysis in high-risk inferior MI; extends randomized evidence for risk-stratified reperfusion.
Key Points
- This analysis aims to evaluate the effectiveness of thrombolytic therapy in inferior myocardial infarction, especially among high-risk patients.
- Assessment of electrocardiographic criteria for identifying high-risk patients with inferior MI.
- Comparison of thrombolytic therapy outcomes in high-risk versus low-risk subsets.
- Review of mortality outcomes associated with thrombolytic therapy.
- For high-risk patients with inferior MI, thrombolytic therapy reduces infarct size and may decrease mortality.
- Thrombolytic therapy shows limited benefit in low-risk patients (baseline risk 2% to 4%) after 6 hours of symptoms.
- No mortality benefit for coronary angioplasty as a primary strategy in inferior MI unless contraindications exist.
Structured PICO
Does reperfusion therapy (thrombolysis or angioplasty) improve mortality in high-risk versus low-risk subsets of patients with inferior myocardial infarction?
P
Population
Patients with inferior myocardial infarction
I
Intervention
Thrombolytic therapy or coronary angioplasty
O
Outcome
Mortality and infarct sizehard clinical
Risk stratification using simple electrocardiographic criteria is crucial in inferior MI to identify high-risk patients who may benefit most from thrombolytic therapy.
Limitations
- No placebo-controlled, randomized trials have analyzed the benefit of thrombolytic therapy for inferior MI in high risk versus low risk subsets.
Cite This Study
Eric Bates (1997) conducted a review in Inferior myocardial infarction. Thrombolytic therapy vs. Coronary angioplasty was evaluated. Thrombolytic therapy for inferior myocardial infarction may primarily benefit high-risk subsets, and there are no mortality data to support using primary angioplasty instead of thrombolysis.